新一轮集采后冠脉“硬通货”大降价

Core Viewpoint - The article discusses the significant price drop of drug-coated balloons (DCBs) following the sixth round of centralized procurement, marking a shift towards a more affordable era for high-value medical consumables in coronary interventions [3][4]. Group 1: Market Dynamics - The price of drug-coated balloons has decreased from over 10,000 yuan to around 2,000 yuan, with some products priced even lower [3][4]. - The annual demand for coronary drug-coated balloons is approximately 610,000 units, while the demand for peripheral drug-coated balloons is only about 70,000 units, indicating a substantial market size difference [5]. - The overall usage of drug-coated balloons is expected to continue rising, with projections estimating over 2 million units by 2030, primarily driven by coronary applications [5]. Group 2: Competitive Landscape - The market for coronary drug-coated balloons is now dominated by domestic manufacturers, with the top three companies holding nearly 48% market share, breaking the previous dominance of foreign giants [6]. - Following the centralized procurement, over 20 manufacturers will compete at similar price points, increasing the pressure on cost control and operational efficiency [5][6]. - Companies that previously relied on high margins from single products will face significant challenges in finding new growth drivers in the evolving market landscape [6].